Abstract
Neuropathic pain, a form of chronic pain caused by injury to or disease of the peripheral or central nervous system, is a formidable therapeutic challenge to clinicians because it does not respond well to traditional pain therapies. Our knowledge about the pathogenesis of neuropathic pain has grown significantly over last 2 decades. Basic research with animal and human models of neuropathic pain has shown that a number of pathophysiological and biochemical changes take place in the nervous system as a result of an insult. This property of the nervous system to adapt morphologically and functionally to external stimuli is known as neuroplasticity and plays a crucial role in the onset and maintenance of pain symptoms. Many similarities between the pathophysiological phenomena observed in some epilepsy models and in neuropathic pain models justify the rational for use of anticonvulsant drugs in the symptomatic management of neuropathic pain disorders.
Carbamazepine, the first anticonvulsant studied in clinical trials, probably alleviates pain by decreasing conductance in Na+ channels and inhibiting ectopic discharges. Results from clinical trials have been positive in the treatment of trigeminal neuralgia, painful diabetic neuropathy and postherpetic neuralgia.
The availability of newer anticonvulsants tested in higher quality clinical trials has marked a new era in the treatment of neuropathic pain. Gabapentin has the most clearly demonstrated analgesic effect for the treatment of neuropathic pain, specifically for treatment of painful diabetic neuropathy and postherpetic neuralgia. Based on the positive results of these studies and its favourable adverse effect profile, gabapentin should be considered the first choice of therapy for neuropathic pain.
Evidence for the efficacy of phenytoin as an antinociceptive agent is, at best, weak to modest. Lamotrigine has good potential to modulate and control neuropathic pain, as shown in 2 controlled clinical trials, although another randomised trial showed no effect. There is potential for phenobarbital, clonazepam, valproic acid, topiramate, pregabalin and tiagabine to have antihyperalgesic and antinociceptive activities based on result in animal models of neuropathic pain, but the efficacy of these drugs in the treatment of human neuropathic pain has not yet been fully determined in clinical trials.
The role of anticonvulsant drugs in the treatment of neuropathic pain is evolving and has been clearly demonstrated with gabapentin and carbamazepine. Further advances in our understanding of the mechanisms underlying neuropathic pain syndromes and well-designed clinical trials should further the opportunities to establish the role of anticonvulsants in the treatment of neuropathic pain.
Similar content being viewed by others
References
Mitchell SW, Morehouse GR, Keen WW. Gunshot wounds and other injuries of nerves. oPhiladelphia: JB Lippincott & Co., 1864
Bennett GJ, Xie YK. A peripheral mononeuropathy in the rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33: 87–107
Casey K. Pain and central nervous system disease: a summary and overview. In: Casey K, editor. Pain and central nervous system disease: central pain syndromes. New York: Raven Press, 1991: 1–11
Wall PD, Gutnick M. Properties of afferent nerve impulses originating from a neuroma. Nature 1974; 248: 740–3
Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990; 43: 205–18
Chung K, Lee BH, Yoon YW, et al. Sympathetic sprouting in the dorsal root ganglia of the injured peripheral nerve in a rat neuropathic pain model. J Comp Neurol 1996; 376: 241–52
DeLeo JA, Coombs DW, Willenbring S, et al. Characterization of a neuropathic pain model: sciatic cryoneurolysis in the rat. Pain 1994; 56: 9–16
Maves TJ, Pechman PS, Gebhart PS, et al. Possible chemical contribution from chronic gut sutures produces disorders of pain sensation like those seen in man. Pain 1993; 54: 57–69
LaMotte RH, Lundberg LE, Todjebork HE. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J Physiol 1992; 448: 749–64
Bennett G. An animal model of neuropathic pain: a review. Muscle Nerve 1993; 16: 1040–8
Dickenson A. Spinal cord pharmacology of pain. Br J Anaesth 1995; 75: 193–200
Neumann S, Doubell TP, Leslie T, et al. Inflammatory pain sensitivity mediated by phenotypic switch in myelinated primary senory neurons. Nature 1996; 384: 360–4
Coderre TJ, Melzack R. The contribution of excitatory aminoacids to central sensitization and persistent nociception after formalin-induced tissue injury. J Neurosci 1992; 12: 3665–70
Jett MF, McGuirk J, Waligora D, et al. The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. Pain 1997; 69: 161–9
Kolzenburg M, Torebjork HE, Wahren LK. Nociceptor modulated central sensitization causes mechanical hyperalgesia in acute chemogenic and chronic neurogenic pain. Brain 1994; 117: 579–91
Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991; 44: 293–9
Ochoa JL, Yarnitsky D. Mechanical hyperalgesias in neuropathic pain patients: dynamic and static subtypes. Ann Neurol 1993; 33: 465–72
Gottrup H, Nielsen J, Arendt-Nielsen L, et al. The relationship between sensor thresholds and mechanical hyperalgesia in nerve injury. Pain 1998; 75: 321–9
Kolzenburg M, Lundberg LE, Torebjork HE. Dynamic and static components of mechanical hyperalgesia in human hairy skin. Pain 1992; 51: 207–19
Cline MA, Ochoa J, Torebjork HE. Chronic hyperalgesia and skin wanning caused by sensitized C nociceptors. Brain 1989; 112: 621–47
LaMotte RH, Thalhammer JG, Torebjork HE, et al. Peripheral neural mechanisms of cutaneous hyperalgesia following mild injury by heat. J Neurosci 1982; 2: 765–81
Coderre TJ, Melzack R. Cutaneous hyperalgesia: contributions of the peripheral and central nervous system to the increase in pain sensitivity after injury. Brain Res 1987; 404: 95–106
Craig AD, Bushnell MC. The thermal grill illusion: unmasking the burn of cold pain. Science 1994; 265: 252–5
Thomas R. Excitatory amino acids in health and disease. J Am Geriatr Soc 1995; 43: 1279–89
McNamara J. Drugs acting on the central nervous system. In: Harman G, Limbird LE, Morinoff PB, et al., editors. Goodman’s and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill, 1996: 461–86
Sotah M, Foong FW. A mechanism of carbamazepine analgesia as shown by bradykinin-induced trigeminal pain. Brain Res Bull 1983; 10: 407–9
Burchiel K. carbamazepine inhibits spontaneous activity in experimental neuromas. Exp Neurol 1988; 102: 249–53
Chapman V, Suzuki R, Chamarette HL, et al. Effects of systemic carbamazepine and gabapentin on spinal neuronal responses in spinal nerve ligated rats. Pain 1998; 75: 261–72
Tanelian DL, Cousins MJ. Combined neurogenic and nociceptive pain in a patient with Pancoast tumor managed by epidural hydromorphone and oral carbamazepine. Pain 1989; 36: 85–8
Tanelian DL, Maclver MB. Analgesic concentrations of lidocaine suppress tonic A-delta and C fiber discharges produced by acute injury. Anesthesiology 1991; 74: 934–6
Blorn S. Trigeminal neuralgia: its treatment with a new anticonvulsant drug. Lancet 1962; I: 839–40
Blom S. Tic douloureoux treated with new anticonvulsants. Arch Neurol 1963; 9: 285–90
Campbell FG, Graham JG, Zikha KJ. Clinical trial of carbamazepine (Tegretol) in trigeminal neuralgia. J Neurosurg Neurol Psychiatry 1966; 29: 265–7
Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Arch Neurol 1968; 19: 129–36
Rull JA, Quibrera R, González-Millan H, et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: double-blind crossover study. Diabetologia 1969; 5: 215–20
Nicol C. A four year double blind randomized study of tegretol in facial pain. Headache 1969; 9: 54–7
Wilton T. Tegretol in the treatment of diabetic neuropathy. S Afr Med J 1974; 27: 869–72
Vilming ST, Lyberg T, Lataste X. Tizanidine in the management of trigeminal neuralgia. Cephalalgia 1986; 6: 181–2
Lindstrom P, Lindblom U. The analgesic effect of tocainide in trigeminal neuralgia. Pain 1987; 28: 45–50
Lechin F, van der Dijs B, Lechin ME, et al. Pimozide therapy for trigeminal neuralgia. Arch Neurol 1989; 46: 960–3
Leijon G, Boivie J. Central post-stroke pain: a controlled trial of amitriptyline and carbamazepine. Pain 1989; 36: 27–36
Gomez-Perez FJ, Choza R, Ríos JM, et al. Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res 1996; 27: 525–9
Saudek CD, Werns S, Reidenberg MM. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther 1977; 22: 196–9
Chadda VS, Mathur MS. Double blind study of the effects of dyphenylhidantoin sodium in diabetic neuropathy. J Assoc Phys India 1978; 26: 403–6
Yajnik S, Singh GP, Singh G, et al. Phenytoin as a coanalgesic in cancer pain. J Pain Symptom Manage 1992; 7: 209–13
McCleane GJ. Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blinded, placebo-controlled, crossover study. Anesth Analg 1999; 89: 985–8
Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988; 38: 1427–32
Drewes AM, Andreasen A, Poulsen LH. Valproate for treatment of chronic central pain after spinal cord injury: a double-blind cross-over study. Paraplegia 1994; 32: 565–9
Zakrzewska JM, Chaudhry Z, Nurmikko TJ, et al. Lamotrigine (Lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain 1997; 73: 223–30
Simpson DM, Olney R, McArthur JC, et al. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 2000; 54: 2115–19
McCleane G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial. Pain 1999; 83: 105–7
Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831–6
Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of post-herpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837–42
Morello CM, Leckband SG, Stoner CP, et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159: 1931–7
Webb J, Kamali F. Analgesic effects of lamotrigine and phenytoin on cold-induced pain: a crossover placebo-controlled study in healthy volunteers. Pain 1998; 76: 357–63
Rockliff BW, Davis EH. Controlled sequential trials of carbamazepine in trigeminal neuralgia. Arch Neurol 1966; 15: 129–36
Gerson GR, Jones RB, Luscombe DK. Studies on the concomitant use of carbamazepine and clomipramine for the relief of post-herpetic neuralgia. Postgrad Med J 1977; 53: 104–9
Spillane J. The treatment of trigeminal neuralgia. Practitioner 1964; 192: 71–7
Raskin NH, Levinson SA, Hoffman PM, et al. Postsympathectomy neuralgia: amelioration with diphenylhidantoin and carbamazepine. Am J Surg 1974; 128: 75–8
Chakrabarti AK, Sawantaray SK. Diabetic peripheral neuropathy: nerve conduction studies before, during, and after carbamazepine therapy. Aust N Z J Med 1976; 6: 565–8
Tomson T, Tybring G, Bertilsson L. carbamazepine therapy in trigeminal neuralgia: clinical effects in relation to plasma concentration. Arch Neurol 1980; 37: 699–703
Taylor J, Espir ML, Brauer S. Long-term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J 1981; 57: 16–8
Peiris JB, Perera GLS, Dvendra SV, et al. Sodium valproate in trigeminal neuralgia. Med J Aust 1980; 2: 278–9
Swerdlow M, Cundill JG. Anticonvulsant drugs in the treatment of lancinating pain: a comparison. Anaesthesia 1981; 36: 1129–32
Caccia M. Clonazepam in facial neuralgia and cluster headache: clinical and electrophysiological study. Eur Neurol 1975; 13: 560–3
Court JE, Kase CS. Treatment of tic douloureux with a new anticonvulsant (Clonazepam). J Neurol Neurosurg Psychiatry 1976; 39: 297–9
Smirne S, Scarlato G. Clonazepam in cranial neuralgias. Med J Aust 1977; 1: 93–4
Bouckhoms AJ, Litman RE. Clonazepam in the treatment of neuralgic pain syndrome. Psychosomatics 1985; 26: 933–6
Rosenberg JM, Harrell C, Ristic H, et al. The effect of gabapentin on neuropathic pain. Clin J Pain 1997; 13: 251–5
Attal N, Brasseur L, Parker F, et al. Effects of gabapentin on different components of peripheral and central neuropathic pain syndromes: a pilot study. Eur Neurol 1998; 40: 191–200
Solaro C, Lunardi GL, Capello E, et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology 1998; 51: 609–11
Canavero S, Bonicalzi V. Lamotrigine control of trigeminal neuralgia. J Neurol 1997; 244: 527–32
Lunardi GL, Leandri M, Albano C, et al. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology 1997; 48: 1714–7
Eisenberg E, Alon N, Ishay A, et al. Lamotrigine in the treatment of painful diabetic neuropathy. Eur J Neurol 1998; 5: 167–73
Cianchetti C, Zuddas A, Randazzo AP, et al. Lamotrigine adjunctive therapy in painful phenomena in MS: preliminary observations [abstract]. Neurology 1999; 53: 433
Potter D, Edwards KR, Bennington VT. Potential role of topiramate in relief of neuropathic pain [abstract]. Neurology 1998; 50: A255
Woodforde JM, Dwyer B, McEwen B. Treatment of post-herpetic neuralgia. Med J Aust 1965; 1: 869–72
Carasso RL, Yehuda S, Streifler M. Clomipramine and amitriptyline in the treatment of severe pain. Int J Neuroscience 1979; 9: 191–4
Watson CP, Evans RJ, Reed K. Amitriptyline versus placebo in pos herpetic neuralgia. Neurology 1982; 32: 671–3
Watson CP, Evans RJ. A comparative trial of amitriptyline and simelidine in post herpetic neuralgia. Pain 1985; 23: 387–94
Facchetti D, Chiroli S, Bascelli C, et al. Gabapentin (GBP) versus carbamazepine in conservative treatment of carpal tunnel syndrome [abstract]. Neurology 1999; 52: A203
Bergouignan M. Cures heureuses de nevralgies faciales essentielles par diphenyl-hidantoinate de soude. Rev Laryngol Otol Rhinol 1942; 63: 34–41
Swerdlow M. Anticonvulsant drugs and chronic pain. Clin Neuropharmacol 1984; 7: 51–82
Yaari Y, Devor M. Phenytoin suppresses spontaneous ectopic discharge in rat sciatic nerve neuromas. Neurosci Lett 1985; 58: 117–22
Duckrow RB, Taub A. The effect of diphenylhydantoin on self-mutilation in rats produced by unilateral multiple dorsal rhizotomy. Exp Neurol 1977; 54: 33–41
Hunter JC, Gogas KR, Hedley LR, et al. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol 1997; 324: 153–60
McQuay H, Carroll D, Jadad A, et al. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995; 311: 1047–52
Ellenberg M. Treatment of diabetic neuropathy with diphenylhidantoin. N Y State J Med 1968; 68: 2653–6
Dallocchio C, Buffa C, Mazzarello P, et al. Gabapentin versus amitriptyline in painful diabetic neuropathy in the elderly. Neurology 1998; 50: A102–3
Savitskaya O. Comparative effectiveness of anti-epileptic preparations in treatment of patients with neuralgia of the trigeminal nerve. Zh Nevropatol Psikhiatr Im S S Korsakova 1980; 80: 530–5
Taylor J. Trigeminal neuralgia treated with G 32.883. J Neurol Neurosurg Psychiatry 1963; 26: 553–4
Braunhofer J, Zikha L. Eroffnet Tegretal neue Therapiemoglichkeiten bei bestimmten neurologischen und endokrinen Krankheitsbildern? Eine klinische elektroenzephalographische und dunnschichtchromatographische Studie. Med Welt 1966; 36: 1875–80
Dalessio DJ, Abbott K. A new agent in the treatment of tic douloureoux. Headache 1966; 5: 103–7
Javid M, Dardenne G. Evaluation of carbamazepine in the management of tic douloureux and other painful disorders. Wis Med J 1969; 68: 95–101
Rasmussen P, Riishede J. Facial pain treated with carbamazepine (Tegretol). Acta Neurol Scand 1970; 46: 385–408
Lemoyne J. Le traitement de la névralgie faciale essentielle par le dimethyl-dithio-hydantoine. Concours Med 1951; 73: 461–3
Jensen H. Die Behandlung der Trigeminusneuralgie mit Diphenylhidantoin. Arztl Wschr 1954; 9: 105–8
Braham I, Saia A. Phenytoin in the treatment of trigeminal and other neuralgias. Lancet 1960; II: 892–3
Cheshire W. Felbamate relieved trigeminal neuralgia. Clin J Pain 1995; 11: 139–42
Valzania F, Strafella A, Nassetti SA, et al. Gabapentin in idiopathic trigeminal neuralgia [abstract]. Neurology 1998; 50: A379
La Spina I, Porazzi D, Maggiolo F, et al. Gabapentin (GBP) in painful AIDS-related neuropathy [abstract]. Neurology 1999; 52: A190
Gatti A, Stefano J, Beretta S, et al. Gabapentin in the treatment of distal symmetric axonopathy in HIV infected patients [abstract]. Neurology 1998; 50: A216
Elliott F, Little A, Milbrandt W. Carbamazepine for phantomlimb phenomena [abstract]. N Engl J Med 1976; 295: 678
Harbison J, Dennehy F, Keating D. Lamotrigine for pain with hyperalgesia. Irish Med J 1997; 90: 56
Bartusch SL, Sanders BJ, D’Alessio JG, et al. Clonazepam for the treatment of lancinating phantom limb pain. Clin J Pain 1996; 12: 59–62
Esmir ML, Millac P. Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol). J Neurol Neurosurg Psychiatry 1970; 33: 528–31
Shibasaki H, Kuroiwa Y. Painful tonic seizure in multiple sclerosis. Arch Neurol 1974; 30: 47–51
Khan O. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998; 51: 611–4
McCleane G. Lamotrigine can reduce neurogenic pain associated with multiple sclerosis. Clin J Pain 1998; 14: 269–70
Chaturvedi S. Phenytoin in reflex sympathetic dystrophy. Pain 1989; 36: 379–80
Mellick GA, Mellick LB. Gabapentin in the management of reflex sympathetic dystrophy. JPain Symptom Manage 1995; 10: 265–6
Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 1996; 12: 56–8
Sist TC, Filadora VA, Miner M, et al. Experience with gabapentin for neuroapthic pain in the head and neck: report of ten cases. Reg Anesth 1997; 22: 473–8
Merren M. Gabapentin for treatment of pain and tremor. South Med J 1998; 91: 739–44
Caraceni A, Zecca E, Martini C, et al. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 1999; 17: 441–5
Gibson JC, White LC. Denervation hyperpathia: a convulsive syndrome of the spinal cord responsive to carbamazepine therapy [letter]. J Neurosurg 1971; 35: 287
Fine W. Post hemiplegic epilepsy in the elderly. BMJ 1967; 1(534): 199–201
Cantor F. Phenytoin treatment of thalamic pain [letter]. BMJ 1972; 2: 590
Agnew DA, Goldberg VD. A brief trial of phenytoin for thalamic pain. Bull Los Angeles Neurol Soc 1976; 41: 9–12
Allen R. Neuropathic pain in the cancer patient. Neurol Clin North Am 1998; 16: 869–7
Sawynok J. GABAergic mechanisms of analgesia: an update. Pharmacol Biochem Behav 1987; 26: 463–74
Yasuda T, Iwamoto T, Ohara M, et al. The novel analgesic compound OT-7100 attenuates mechanical nociceptive responses in animal models of acute and peripheral neuropathic hyperalgesia. Jap J Pharmacol 1999; 79: 65–73
Bouckoms A. Intravenous lorazepam for pain relief of intractable neuralgia. Pain 1987; Suppl. 4: S347
Ko GY, Brown-Croyts LM, Teyler T. The effects of anticonvulsant drugs on NMDA-EPSP, AMPA-EPSP, and GABA-IPSP in the rat hippoccampus. Brain Res Bull 1997; 42: 297–302
Shuto K, Nishiyaki T. Sodium dipropylacetate. Pharmacometrics 1970; 4: 937–49
Mesdjian E, DeFeudis FV, Valli M, et al. Antinociceptive action of sodium valproate in the mouse. Gen Pharmacol 1983; 14: 697–9
Abulaban FS, Dhariwal MAH, Al-Bekairi AM, et al. Anti-nociceptive activity of sodium valproate in mice after chronic treatment. Gen Pharmacol 1997; 29: 463–7
Lee WS, Limmroth V, Ayala C, et al. Peripheral GABA-A receptor-mediated effects of sodium valproate on durai plasma protein extravasation to subsance P and trigeminal stimulation. Br J Pharmacol 1995; 116: 1661–7
Cutrer FM, Moskowitz MA. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache 1996; 36: 579–85
Alley KO, Kulkarni SK. GABAergic agents-induced anti-nociceptive effect in mice. Methods Find Exp Clin Pharmacol 1989; 11: 597–601
Raftery H. The management of post herpetic pain using sodium valproate and amitriptyline. Irish Med J 1979; 72: 399–401
Bowsher D, Lahuerta J, Nelson A. A case of tabes dorsalis with tonic pupils and lightning pains relieved by sodium valproate. J Neurol Neurosurg Psychiatry 1987; 50: 239–41
Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 27: 490–7
Nakamura-Craig M, Folienfant R. Analgesic reffects of lamotrigine in an experimental model of neuropathic pain in rats [abstract]. Br J Pharmacol 1992; 107: 337P
Nakamura-Craig M, Folienfant R. Effect of lamotrigine in the acute and chronic hyperalgesia induced by PGE2 and in the chronic hyperalgesia in rats with streptozotocin-induced diabetes. Pain 1995; 63: 33–7
Klamt J. Effects of intrathecally administered lamotrigine, a glutamate release inhibitor, on short- and long-term models of hyperalgesia in rats. Anesthesiology 1998; 88: 487–94
Kukushkin ML, Danilova EI, Grafova VN, et al. Effect of lamotrigine on the development of neurogenic pain syndrome in rats. Bull Exp Biol Med 1998; 125: 517–21
Taylor CP, Gee NS, Su T-Z, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29: 233–49
Field MJ, McCleary S, Hughes J, et al. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 1999; 80: 391–8
Abdi S, Lee DH, JM. C. The anti-allodynic effects of amytriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg 1998; 87: 1360–6
Pan H-L, Eisenach JC, Chung JM. Gabapentin suppresses ectopic nerve discharges. J Pharmacol Exp Ther 1999; 288: 1026–30
Gillin S, Sorkin LS. Gabapentin reverses the allodynia produced by the administration of anti-GD2 ganglioside, and immuno-therapeutic drug. Anesth Analg 1998; 86: 111–6
Petroff OA, Rothman DL, Behar KL, et al. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996; 39: 95–9
Mancardi G, Messmer Uccelli M, Murialdo A, et al. Gabapentin is effective in treating nocturnal painful spasms in muktiple sclerosis [abstract]. Neurology 1999; 52: A134
Vinik A, Fonseca V, Lamoeaux L, et al. Neurontin (Gabapentin, GBP) improves quality of life (QOL) in patients with painful diabetic peripheral neuropathy [abstract]. Diabetes 1998; 46: A374
Gorson KC, Schott C, Rand WM, et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo-controlled, double-blind, crossover trial [abstract]. Neurology 1998; 50: A103
Morello CM, Leckbrand SG, Stoner CP. Effect of gabapentin compared to amitriptyline on pain in diabetic peripheral neuropathy [abstract]. Diabetes 1998; 47: A134
Edwards K, Glantz MJ, Button J, et al. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study [abstract S15.001]. Neurology 2000; 54S3: A81
Iacobellis D, Allen R, Lamoreaux L, et al. A double-blind, placebo-control trial of pregabalin for the treatment of painful diabetic peripheral neuropathy [abstract P03.049]. Neurology 2000; 54 S3: A177
Schneidermann J. Topiramate: pharmacokinetics and pharmacodinamics. Can J Neurol Sci 1998; 25: S3–5
Sajwa ZH, Sami N, Warfield CA, et al. Topiramate relieves refractory intercostal neuralgia. Neurology 1999; 52: 1917
González-Darder JM, Ortega-Alvaro A, Rui-Franzi I, et al. Antinociceptive effects of phenobarbital in ‘tail-flick’ and deafferentation pain. Anesth Analg 1992; 75: 81–6
Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-Methyl-D-aspartate and GABA-A receptors. Ann Neurol 1994; 36: 677–8
Imamura Y, Bennett GJ. Felbamate relieves several abnormal pain sensations in rats with an experimental peripheral neuropathy. J Pharm Exp Ther 1995; 275: 177–82
Alves ND, de Castro-Costa CM, de Carvalho AM, et al. Possible analgesic effect of vigabatrin in animal experimental chronic neuropathic pain. Arq Neuropsiquiatr 1999; 57: 916–20
Leach JP, Brodie MJ. Tiagabine. Lancet 1998; 351: 203–7
Giardina WJ, Decker MW, Porsolt RD, et al. An evaluation of the GAB A uptake blocker tiagabine in animal models of neuropathic and nociceptive pain. Drug Dev Res 1998; 44: 106–13
Ipponi A, Lamberti C, Medica A, et al. Tiagabine nociception in rodents depends on GABA-B receptor activation: parallel antinociception testing and medial hypothalamus GABA microdyalisis. Eur J Pharmacol 1999; 368: 205–11
Yarnitsky D. Quantitative sensory testing. Muscle Nerve 1997; 20: 198–204
Bouhassira D, Attal N, Willer JC, et al. Painful and painless peripheral sensory neuropathies due to HIV infection: a comparison using quantitative sensory stimulation. Pain 1999; 80: 265–72
Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the neuropathic pain scale. Neurology 1997; 48: 332–8
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tremont-Lukats, I.W., Megeff, C. & Backonja, MM. Anticonvulsants for Neuropathic Pain Syndromes. Drugs 60, 1029–1052 (2000). https://doi.org/10.2165/00003495-200060050-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200060050-00005